These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 18377338)

  • 1. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
    Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
    J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.
    Cozzolino M; Galassi A; Gallieni M; Brancaccio D
    Curr Vasc Pharmacol; 2008 Apr; 6(2):148-53. PubMed ID: 18393917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
    Xie Y; Su P; Sun Y; Zhang H; Zhao R; Li L; Meng L
    BMC Nephrol; 2017 Aug; 18(1):272. PubMed ID: 28841848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM
    Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular calcification in chronic kidney failure: role of vitamin D receptor.
    Wu-Wong JR; Melnick J
    Curr Opin Investig Drugs; 2007 Mar; 8(3):237-47. PubMed ID: 17408120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of paricalcitol in patients with chronic kidney disease.
    Dyer CA
    Expert Opin Drug Saf; 2013 Sep; 12(5):717-28. PubMed ID: 23621417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D treatment in chronic kidney disease.
    Andress DL
    Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
    Noonan W; Koch K; Nakane M; Ma J; Dixon D; Bolin A; Reinhart G
    Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.
    Dobrez DG; Mathes A; Amdahl M; Marx SE; Melnick JZ; Sprague SM
    Nephrol Dial Transplant; 2004 May; 19(5):1174-81. PubMed ID: 15004264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
    Brancaccio D; Bommer J; Coyne D
    Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised clinical study of alfacalcidol and paricalcitol.
    Hansen D
    Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D; Acharya M; Qiu P; Abboud H; Batlle D; Rosansky S; Fadem S; Levine B; Williams L; Andress DL; Sprague SM
    Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
    Andress D
    Drugs; 2007; 67(14):1999-2012. PubMed ID: 17883284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
    Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
    Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
    Wu-Wong JR; Tian J; Nakane M; Ma J; Fey TA; Kroeger P; Fryer RM; Reinhart GA
    Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Paricalcitol - a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease].
    Matuszkiewicz-Rowińska J; Żebrowski P
    Wiad Lek; 2016; 69(5):756-759. PubMed ID: 28033603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.